Previous studies indicated that breast cancer cell line BT474 would undergo epithelial mesenchymal transition (EMT) and possess triple negative phenotype (BT474-PTEN-LTT, LTT) after trastuzumab treatment2. This evidence concerns the gene PTEN and breast carcinoma.